For Aqemia SA, the year got off to a good start, as one of its pharma partners, Les Laboratoires Servier SAS, extended an existing collaboration to drug a supposedly undruggable immuno-oncology target, using its Launchpad artificial intelligence platform.
LONDON – Following on from the $25 million up-front payment received on sealing their recent research collaboration, Mina Therapeutics Ltd. is now in line for a $15 million equity investment from Eli Lilly and Co. Inc.
A collection of CAR T-cell programs originally licensed by Precision Biosciences Inc. to Baxalta Inc. in a $1.6 billion deal are, after handoffs to Shire and Servier SAS, back where they began. Precision said April 15 it would reacquire all development and commercial rights to the programs, including two clinical-stage CD19-targeting allogeneic CAR T candidates, from Servier for $1.25 million in cash, plus the waiver of earned but as-yet unpaid milestones totaling $18.75 million.
The latest global regulatory news, changes and updates affecting biopharma, including: HIV trial networks streamlined; Grants to advance use of RWD, RWE; GAO, National Academies, report on AI in health care; ICER not sold on roxadustat; Teva, Cephalon latest EC targets; Hungary looks to Russian vaccine.